Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 159

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors

Razavi, Pedram, Dickler, Maura N., Shah, Payal D., Toy, Weiyi, Brown, David N., Won, Helen H., Li, Bob T., Shen, Ronglai, Vasan, Neil, Modi, Shanu, Jhaveri, Komal, Caravella, Betty Ann, Patil, Sujata, Selenica, Pier, Zamora, Stephen, Cowan, Aimee M., Comen, Elizabeth, Singh, Andy, Covey, Anne, Berger, Michael F., Hudis, Clifford A., Norton, Larry, Nagy, Rebecca J., Odegaard, Justin I., Lanman, Richard B., Solit, David B., Robson, Mark E., Lacouture, Mario E., Brogi, Edi, Reis-Filho, Jorge S., Moynahan, Mary Ellen, Scaltriti, Maurizio, Chandarlapaty, Sarat · 2020 · Nature Cancer

Abstract

Alpelisib is a selective inhibitor of phosphoinositide 3-kinase (PI3K)α, shown to improve outcomes for PIK3CA-mutant, hormone receptor–positive metastatic breast cancers when combined with antiestrogen therapy. To uncover mechanisms of resistance, we conducted a detailed, longitudinal analysis of tumor and plasma circulating tumor DNA (ctDNA) among such patients from a phase I/II trial combining alpelisib with an aromatase inhibitor (NCT01870505). The trial’s primary objective was to establish safety with maculopapular rash emerging as the most common grade 3 adverse event (33%). Among 44 evaluable patients, the observed clinical benefit rate was 52%. Correlating genetic alterations with outcome, we identified loss-of-function PTEN mutations in 25% of patients with resistance. ESR1 activating mutations also expanded in number and allele fraction during treatment and were associated with resistance. These data indicate that genomic alterations that mediate resistance to alpelisib or antiestrogen may promote disease progression and highlight PTEN loss as a recurrent mechanism of resistance to PI3Kα inhibition. Chandarlapaty and colleagues use longitudinal ctDNA samples to identify genomic alterations in PTEN and ESR1 associated with resistance in a phase I/II trial of a PI3K inhibitor and aromatase inhibition for hormone receptor–positive metastatic breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s43018-020-0047-1

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

See all 159

Metadata

Authors
Razavi, P., Dickler, M. N., Shah, P. D., Toy, W., Brown, D. N., Won, H. H., Li, B. T., Shen, R., Vasan, N., Modi, S., Jhaveri, K., Caravella, B. A., Patil, S., Selenica, P., Zamora, S., Cowan, A. M., Comen, E., Singh, A., Covey, A., Berger, M. F., Hudis, C. A., Norton, L., Nagy, R. J., Odegaard, J. I., Lanman, R. B., Solit, D. B., Robson, M. E., Lacouture, M. E., Brogi, E., Reis-Filho, J. S., Moynahan, M. E., Scaltriti, M., & Chandarlapaty, S.
Venue
Nature Cancer
Published
2020-03-23
Volume
1
Issue
4
Pages
382-393
ISSN
2662-1347 (ISSN-L)
OpenAlex
W3012647537
Cited by
159
References
13
FWCI
12.31
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. https://app.cochat.ai/papers/10.1038/s43018-020-0047-1
The paper
Razavi, P., Dickler, M. N., Shah, P. D., Toy, W., Brown, D. N., Won, H. H., Li, B. T., Shen, R., Vasan, N., Modi, S., Jhaveri, K., Caravella, B. A., Patil, S., Selenica, P., Zamora, S., Cowan, A. M., Comen, E., Singh, A., Covey, A., . . . Chandarlapaty, S. (2020). Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors. Nature Cancer. https://doi.org/10.1038/s43018-020-0047-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.